Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement
Munich, Germany, 25 January 2017
WILEX AG (ISIN DE000A11QVV0 / WL6 / FWB) today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, signed the license agreement with the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) in Berlin covering BCMA antibodies. The license agreement follows an option agreement signed in September 2016.
Financial details are confidential but will not have a material impact on WILEX’ cash reach.
As a result of a selection and optimization process of the BCMA antibodies, the ATAC candidate HDP-101 was selected and is currently being prepared for clinical development that could start by the end of 2018.
24 January 2017: Am MDC entwickelte Tumor-Antikörper gegen Multiples Myelom gehen in die Anwendung (in German only)
19 September 2016: Heidelberg Pharma Signs Option Agreement with Max Delbrück Center
About Max Delbrück Center
The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) was founded in January 1992 on the recommendation of the German Council of Science and Humanities (“Wissenschaftsrat”) with the goal of linking basic science to clinical research. It was named for Max Delbrück, a physicist, biologist, and Nobel Prize winner. Currently the institute employs more than 1600 people from nearly 60 countries; over 1300 of those are directly involved in research. The MDC’s annual budget is over 80 million Euros, along with substantial third-party funding obtained by individual scientific groups. As is the case with all Helmholtz institutes, the MDC receives 90 percent of its funding from the federal government and 10 percent from Berlin, the state where it resides.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company. The Company’s research and development work is conducted by its subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the company’s own therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate is a BCMA ATAC for multiple myeloma. WILEX’s clinical assets MESUPRON® and REDECTANE® have been partnered, while RENCAREX® is available for out-licensing and further development. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.wilex.com and www.heidelberg-pharma.com.
About Heidelberg Pharma’s proprietary ATAC technology
Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer and inflammatory diseases. ATACs are ADCs that are bound to highly potent amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combatting even quiescent tumor cells.
|Corporate Communications||IR/PR support|
|WILEX AG||MC Services AG|
|Sylvia Wimmer||Katja Arnold (CIRO) - Executive Director|
|Tel.: +49 (0)89 41 31 38-29||Tel.: +49 (0)89 210 228-40|
|Email: investors[at]wilex.com||Email: katja.arnold[at]mc-services.eu|
|Grillparzerstr. 18, 81675 Munich, Germany|
|Heidelberg Pharma GmbH|
|Dr. Marcel Linssen|
|CBO, Executive Vice President|
|Tel.: +49 (0)6203 1009-40|
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.